INTRODUCTION {#sec1_1}
============

Flagellated protozoa of the genus *Giardia* comprise several species and are ubiquitous. The parasite infects the intestinal tract of a wide range of vertebrate hosts belonging to different phyla, including avian, reptile, mammal, and human ([@B1]--[@B3]). Infection in humans is caused by *Giardia intestinalis* (synonyms: *G. lamblia, G. duodenalis*), which is molecularly classified into seven genotypes (assemblages), namely A-G ([@B4]--[@B5]). Humans are mainly infected by genotype A and/or B ([@B6]). *Giardia*-associated infection is the most common intestinal infestation worldwide ([@B7]). The worldwide incidence was estimated at 2.8×10^8^ infections per year ([@B8]). Humans are infected either by faecal-oral transmission through fomites or by ingestion of parasite cysts in contaminated drinking-water and less often in food ([@B9]). Excystation of the gastric acid-stimulated cysts occurs in the host intestine, and the trophozoites subsequently infect the intestinal mucosa, multiply, and colonize the mucosal surface, thus, interfering with the host\'s nutrient absorption ([@B10]). Although 60--80% of *G. intestinalis*-associated infections are asymptomatic, clinical manifestations ranging from mild to severe diarrhoea with bloating and abdominal pain are not infrequent, especially among young children and the elderly ([@B9], [@B10]). Chronic giardiasis as well may cause long-term growth retardation due to nutritional deficiencies ([@B11]).

In Thailand, the prevalence of human giardiasis ranged from 1.25% to 37.7% ([@B12]). The incidence varies depending on age, living circumstances, environmental sanitation, and personal hygiene. *G. intestinalis* is a common parasite in Thailand and in other developing countries ([@B12]--[@B16]). The incidence among Thai orphans is 37.7--85.5% ([@B17], [@B18]). Nevertheless, this parasitic infestation did not receive much attention or concern so far. In this study, *G. intestinalis* isolates from asymptomatic subjects and from those with gastrointestinal symptoms were genetically typed. The data provide additional molecular information on human *G. intestinalis* isolates which was so far lacking from Thailand.

MATERIALS AND METHODS {#sec1_2}
=====================

Human subjects, stool samples, and purification of *G. intestinalis* cysts {#sec1_2_1}
--------------------------------------------------------------------------

Of 6,967 subjects included, 6,018 were Bangkok inhabitants who visited the Siriraj Hospital during December 2006--July 2007 for health check-ups. *G. intestinalis* cysts were microscopically found in stools of 22 subjects (0.36%). Seventeen subjects (10 male, 7 female) were asymptomatic (Group 1), and five subjects (3 male, 2 female) had gastrointestinal symptoms (Group 2), including one or more of the following complaints: (chronic) diarrhoea with either soft, mucoid, or watery stool, and/or abdominal pain. The other 949 subjects were inhabitants of Ratchaburi province (located nearly 100 km southwest of Bangkok) recruited during a community survey conducted in September 2007. *G. intestinalis* cysts were found in 39 subjects (4.1%). Twenty-six (12 male, 14 female) of these were asymptomatic (Group 3), and 13 (5 male, 8 female) complained of intestinal symptoms (Group 4). Background information of the *G. intestinalis*-infected subjects is presented in [Table 1](#T1){ref-type="table"}.

###### 

Background information on the subjects from whom *G. intestinalis* cysts were collected, the results of gene segment amplifications, and the assemblage/sub-assemblage classification of the cysts

  Source                             Group             No.   Age (years)   Sex     PCR amplicon   Assemblage(s)[\*](#TF1-001){ref-type="table-fn"}   Sub-assemblage(s)[\*\*](#TF1-002){ref-type="table-fn"}              
  ---------------------------------- ----------------- ----- ------------- ------- -------------- -------------------------------------------------- -------------------------------------------------------- ---- ----- ----------
  Siriraj                            1 (healthy)       1     7             F       \-             \+                                                 \+                                                       \+   A+B   AII+BIII
  Hospital                                             2     14            M       \+             \+                                                 \+                                                       \-   A+B   AII
                                                       3     34            M       \-             \+                                                 \+                                                       \+   B     BIV
                                                       4     57            M       \+             \+                                                 \+                                                       \+   B     BIV
                                                       5     15            F       \-             \+                                                 \+                                                       \+   A+B   AII+BIII
                                                       6     2             M       \-             \+                                                 \+                                                       \-   B     
                                                       7     47            F       \-             \+                                                 \-                                                       \-   B     
                                                       8     33            F       \-             \-                                                 \-                                                       \-   B     
                                                       9     18            F       \-             \+                                                 \-                                                       \-   B     
                                                       10    37            M       \-             \+                                                 \+                                                       \-   A+B   AII
                                                       11    44            M       \+             \+                                                 \+                                                       \-   A+B   AII
                                                       12    32            F       \-             \-                                                 \-                                                       \-   B     
                                                       13    9             M       \+             \+                                                 \+                                                       \-   A+B   AII
                                                       14    55            M       \-             \+                                                 \-                                                       \-   B     
                                                       15    35            M       \-             \+                                                 \-                                                       \-   B     
                                                       16    58            F       \-             \-                                                 \-                                                       \-   B     
                                                       17    70            M       \+             \+                                                 \+                                                       \+   A+B   AII+BIV
                                     2 (symptomatic)   18    38            F       \-             \+                                                 \+                                                       \+   A+B   AII+BIII
                                                       19    50            M       \-             \+                                                 \+                                                       \+   A+B   AII+BIV
                                                       20    9             M       \+             \-                                                 \-                                                       \-   B     
                                                       21    54            M       \+             \+                                                 \-                                                       \-   B     
                                                       22    66            F       \+             \+                                                 \+                                                       \+   A+B   AI+BIV
  Ratchaburi                         3 (healthy)       23    4             M       \+             \+                                                 \+                                                       \-   B     
  province                                             24    7             F       \-             \+                                                 \+                                                       \-   A     AII
                                                       25    29            M       \-             \-                                                 \-                                                       \-   B     
                                                       26    2             F       \-             \+                                                 \+                                                       \-   B     
                                                       27    3             F       \-             \-                                                 \-                                                       \-   B     
                                                       28    4             F       \-             \-                                                 \-                                                       \-   B     
                                                       29    6             F       \+             \+                                                 \+                                                       \-   B     
                                                       30    9             M       \-             \+                                                 \-                                                       \+   A+B   AII+BIV
                                                       31    11            F       \-             \+                                                 \+                                                       \-   A+B   AII
                                                       32    3             M       \-             \-                                                 \-                                                       \+   B     BIV
                                                       33    9             M       \-             \+                                                 \-                                                       \-   A     AII
                                                       34    12            M       \-             \+                                                 \+                                                       \-   B     
                                                       35    10            F       \-             \+                                                 \+                                                       \-   B     
                                                       36    31            M       \-             \+                                                 \+                                                       \+   B     BIV
                                                       37    43            F       \-             \+                                                 \+                                                       \-   A+B   AII
                                                       38    42            M       \-             \-                                                 \-                                                       \+   B     BIV
                                                       39    69            F       \-             \-                                                 \-                                                       \-   A+B   
                                                       40    6             F       \-             \+                                                 \-                                                       \-   B     
                                                       41    5             F       \+             \+                                                 \+                                                       \+   A+B   AII+BIII
                                                       42    13            M       \-             \-                                                 \-                                                       \+   A+B   BIV
                                                       43    10            M       \-             \+                                                 \+                                                       \-   A     AII
                                                       44    4             F       \-             \+                                                 \-                                                       \-   A     AII
                                                       45    7             M       \-             \+                                                 \+                                                       \-   A+B   AII
                                                       46    13            F       \+             \+                                                 \-                                                       \-   B     
                                                       47    14            M       \-             \-                                                 \-                                                       \-   A+B   
                                                       48    3             F       \-             \-                                                 \-                                                       \-   B     
                                     4 (symptomatic)   49    5             M       \-             \-                                                 \-                                                       \-   B     
                                                       50    3             F       \+             \+                                                 \+                                                       \+   A+B   AII+BIII
                                                       51    7             F       \-             \-                                                 \-                                                       \-   A+B   
                                                       52    8             F       \-             \-                                                 \-                                                       \+   A+B   BIII
                                                       53    2             F       \-             \-                                                 \-                                                       \+   B     BIV
                                                       54    4             M       \-             \+                                                 \-                                                       \+   B     BIII
                                                       55    7             M       \-             \+                                                 \+                                                       \+   A+B   AII+BIII
                                                       56    6             M       \-             \+                                                 \-                                                       \+   A+B   AI+BIII
                                                       57    6             M       \+             \+                                                 \-                                                       \-   B     
                                                       58    50            F       \-             \+                                                 \-                                                       \-   A     AII
                                                       59    4             F       \-             \+                                                 \-                                                       \+   A+B   AII+BIII
                                                       60    5             F       \-             \+                                                 \-                                                       \+   A+B   AI+BIV
                                                       61    5             F       \-             \+                                                 \+                                                       \-   B     
  Number of detected/total samples                           14/61         44/61   28/61          22/61                                                                                                                  

\*Assemblage classification was based on the results of *tpi* amplification (assemblage A was positive for the 148-bp *tpi* amplicon, and assemblage B was positive for the 81-bp *tpi* amplicon);

\*\*Sub-assemblages were based on the RFLP of the 384 β-*giardin* and *gdh* amplicons (see text);

PCR=Polymerase chain reaction;

RFLP=Restriction fragment length polymorphism

The *G. intestinalis* cysts were purified from 61 stool samples as previously described with modifications ([@B18]). Briefly, 20 g of each sample were stirred in distilled water and filtered through a 70-μm strainer. Aliquots of each preparation were overlaid onto an appropriate volume of a 4-M sucrose solution contained in a tube, and the tube was centrifuged at 850 × g for 10 minutes. The *G. intestinalis* cysts were then collected from the water-sucrose interface, washed several times with normal saline solution, and kept at −70 °C until genomic DNA extraction performed within one month.

DNA isolation, polymerase chain reaction amplification of gene segments, DNA sequencing, and identification of assemblages {#sec1_2_2}
--------------------------------------------------------------------------------------------------------------------------

The genomic DNA of the *G. intestinalis* cysts of all the subjects was extracted using a genomic DNA extraction-kit (SBS Gentech, China) according to the instructions of the manufacturer. These DNA preparations, together with the 11 oligonucleotide primer sequences presented in [Table 2](#T2){ref-type="table"}, were then used for polymerase chain reaction (PCR) amplifications of the 292-bp *ssrRNA* ([@B19]), 753-bp and 384-bp β-*giardin* ([@B19]), 432-bp *gdh* ([@B20]), and 148-bp and 81-bp *tpi* segments which were specific for assemblage A and B respectively ([@B21]), under PCR conditions previously described ([@B19]--[@B21]) using *pfu* DNA polymerase (Fermebtus, Lithuania). The sizes of the DNA amplicons were determined by a 1.0% agarose gel electrophoresis, ethidium bromide staining, and ultraviolet transillumination compared to a 1-kb DNA ladder run concurrently in the same gel slab. The DNA sequences of each PCR amplicon were verified using the ABI Prism BigDye Terminator Cycle Sequencing kit (Applied Biosystems, USA). The DNA sequences of randomly-selected cysts of subjects with symptomatic giardiasis belonging to different assemblages/sub-assemblages were aligned with the database sequences.

###### 

Oligonucleotide primers used in this study

  Gene                  Primer   Sequence                            Amplicon size (bp)   Reference
  --------------------- -------- ----------------------------------- -------------------- -----------
  *ssrRNA*              F-H11    5-CATCCGGTCGATCCTGCC-3              292                  [@B19]
                        R-RH4    5-AGTCGAACCCTGATTCTCCGCCCAGG-3                           
  384-bp β-*giardin*    F-376    5-CATAACGACGCCATCGCGGCTCTCAGGAA-3   384                  [@B19]
                        R-G759   5-GAGGCCGCCCTGGATCTTCGAGACGAC-3                          
  753-bp β-*giardin*    F-G7     5-AAGCCCGACGACCTCACCCGCAGTGC-3      753                  [@B19]
                        R-G759   5-GAGGCCGCCCTGGATCTTCGAGACGAC-3                          
  *gdh*-primary PCR     F-gdhe   5-TCAACGTYAAYCGYGGYTTCCGT-3                              
                        R-gdhi   5-GTTRTCCTTGCACATCTCC-3                                  
  *gdh*-secondary PCR   F-gdhi   5-CAGTACAACTCYGCTCTCGG-3            432                  [@B20]
                        R-gdhe   5-GTTRTCCTTGCACATCTCC-3                                  
  *tpi*-A               F-tpiA   5-GGAGACCGACGAGCAAAGC-3             148                  [@B21]
                        R-tpiA   5-CTTGCCAAGCGCCTCAA-3                                    
  *tpi*-B               F-tpiB   5-AATAGCAGCACARAACGTGTATCTG-3'      81                   [@B21]
                        R-tpiB   5-CCCATGTCCAGCAGCATCT-3                                  

PCR=Polymerase chain reaction

Restriction fragment length polymorphism for determining *G. intestinalis* sub-assemblages {#sec1_2_3}
------------------------------------------------------------------------------------------

For the determination of the A sub-assemblages, the PCR product of the 384-bp β-*giardin* was digested with *Hha*I restriction endonuclease ([@B19]). The amplicon of the 432-bp *gdh* was digested with *Rsa*I for the determination of the B sub-assemblages ([@B20]). Each digested DNA preparation was subjected to a 12.5% acrylamide gel electrophoresis and ethidium bromide staining. A low-range molecular weight DNA ladder (Fermentas) was included as a size marker in each gel slab. The banding patterns of the DNA restriction fragments were recorded using a gel documentation system (Gel Doc 2000, BioRad, USA) and observed visually. The accuracy of the sub-assemblage classification was verified by aligning the nucleotide sequences with the respective sub-assemblage sequences of the database using the computer software package Clustal_X 1.83 ([@B22]).

Statistical analysis {#sec1_2_4}
--------------------

The Epi Info software (version 6) was used for analyzing data. Comparison of the prevalence of different *G. intestinalis* assemblages in subjects with symptomatic giardiasis and in the asymptomatic subjects and the prevalence of each assemblage between the symptomatic and the asymptomatic subjects was made using chi-square test. A p value of \<0.05 was considered statistically significant.

The Ethics Committee of the Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, approved the study.

RESULTS {#sec1_3}
=======

PCR for detection of *G. intestinalis* genes {#sec1_3_1}
--------------------------------------------

The 292-bp *ssrRNA*, 753-bp β-*giardin*, 384-bp β-*giardin*, and 432-bp *gdh* segments could be amplified from 14 (23%), 28 (46%), 44 (72%), and 22 (36%) of the 61 cyst preparations respectively. Nevertheless, all the 61 samples gave positive *tpi* amplicons (100% sensitivity), either of the 148- or the 81-bp gene segments. [Figure 1](#F1){ref-type="fig"} shows the representative amplicons of the individual gene segments. The results of the PCR amplifications of the gene segments of all the cyst preparations are shown in [Table 1](#T1){ref-type="table"}.

![PCR amplicons of β-*giardin, ssrRNA, gdh,* and *tpi* segments](jhpn0028-0042_f01){#F1}

Assemblage identification {#sec1_3_2}
-------------------------

Five (8%) of the 61 cyst preparations were positive for the 148 bp-*tpi* amplicon only, implying assemblage A for these *G. intestinalis* cysts, and 31 (51%) were positive for the 81-bp *tpi* amplicon only, implying assemblage B. The remaining 25 samples (41%) were positive for both *tpi* gene amplicons, indicating the presence of a mixed population of these two assemblages ([Table 1](#T1){ref-type="table"}). Of the 18 symptomatic subjects (5 of Group 2 and 13 of Group 4), one (5.6%) had assemblage A, seven (38.8%) had assemblage B, and 10 (55.6%) had the mixture ([Table 3](#T3){ref-type="table"}). Of the 43 asymptomatic individuals, four (9.3%) had assemblage A, 24 (55.8%) had assemblage B, and 15 (34.9%) had both ([Table 3](#T3){ref-type="table"}). The prevalence of assemblage A in both symptomatic and asymptomatic subjects was significantly lower than that of the B and A+B assemblage(s) (p\<0.05%) but the prevalence of B and A+B was not significantly different (p\>0.05). There was no significant difference in the prevalence of the individual *G. intestinalis* assemblages between the symptomatic and the asymptomatic subjects (p\>0.05) ([Table 3](#T3){ref-type="table"}).

###### 

Prevalence of *Giardia intestinalis* cyst assemblage(s)

  *Giardia intestinalis* genotype   Symptomatic (n=18)   Asymptomatic (n=43)                              
  --------------------------------- -------------------- ------------------------------------------- ---- -------------------------------------------
  A                                 1                    5.6[\*](#TF3-001){ref-type="table-fn"}      4    9.3[\*](#TF3-001){ref-type="table-fn"}
  B                                 7                    38.8[\*\*](#TF3-001){ref-type="table-fn"}   24   55.8[\*\*](#TF3-001){ref-type="table-fn"}
  Mixed types                       10                   55.6[\*\*](#TF3-001){ref-type="table-fn"}   15   34.9[\*\*](#TF3-001){ref-type="table-fn"}

Entries with different superscripts (\*,\*\*) are statistically different at p\<0.05

Sub-assemblage classification {#sec1_3_3}
-----------------------------

Of the 44 subjects whose *G. intestinalis* cysts were positive for the 384 bp β-*giardin* gene amplicon, 25 were positive for the 148-bp *tpi* amplicon, i.e. assemblage A cysts (5 subjects had A only, and 20 subjects had A+B) ([Table 1](#T1){ref-type="table"}). To determine the A sub-assemblages, the 384-bp β-*giardin* amplicons of these samples were cut by *Hha*I restriction endonuclease, and the RFLP patterns of the DNA fragments were studied. Only three (12%) (no. 22 of Group 2 and no. 56 and 60 of Group 4) of the 25 subjects had cysts belonging to sub-assemblage AI, as indicated by the presence of three DNA bands at 193, 100 and 70 bp (lane 1, [Fig. 2](#F2){ref-type="fig"}). The remaining 22 subjects (88%) (no. 1, 2, 5, 10, 11, 13, and 17 of Group 1, no. 18 and 19 of Group 2, no. 24, 30, 31, 33, 37, 41, and 43--45 of Group 3, and no. 50, 55, 58, and 59 of Group 4) had sub-assemblage AII, determined by the presence of two DNA bands at 210 and 70 bp (lane 2, [Fig. 2](#F2){ref-type="fig"}).

![DNA-banding patterns (RFLP) of the 384-bp β-*giardin* gene amplicons cut by the *Hha*I restriction endonuclease](jhpn0028-0042_f02){#F2}

Of the 56 subjects who had *G. intestinalis* cysts positive for the 81-bp *tpi* segments (31 of assemblage B alone and 25 of assemblages A+B) ([Table 1](#T1){ref-type="table"}), the 432-bp *gdh* segments could be amplified only from 22, i.e. no. 1, 3--5, and 17 of Group 1, no. 18, 19, and 22 of Group 2, no. 30, 32, 36, 38, 41, and 42 of Group 3, and no. 50, 52--56, 59, and 60 of Group 4 ([Table 1](#T1){ref-type="table"}). The *gdh* amplicons of these 22 subjects were individually cut by *Rsa*I endonuclease, and the digested products were subjected to agarose gel electrophoresis and ethidium bromide staining for determining the B sub-assemblages. Ten (45.5%) subjects revealed *G. intestinalis* cysts of the BIII sub-assemblage (no. 1, 5, 18, 41, 50, 52, 54--56, and 59), defined by the presence of DNA bands at 290 and 130 bp (lane 1, [Fig. 3](#F3){ref-type="fig"}) while the other 12 subjects (54.5%) harboured cysts of the BIV sub-assemblage, determined by the presence of a 430 DNA band (lane 2, [Fig. 3](#F3){ref-type="fig"}). The distribution of *G. intestinalis* sub-assemblages among the symptomatic and asymptomatic subjects is shown in [Table 4](#T4){ref-type="table"}. There was no significant difference between the *G. intestinalis* sub-assemblages of the symptomatic and asymptomatic subjects.

###### 

Distribution of *Giardia intestinalis* assemblage(s) and sub-assemblage(s) among symptomatic and asymptomatic Thai subjects

  *Giardia intestinalis* genotype   Symptomatic (n=18)   Asymptomatic (n=43)               
  --------------------------------- -------------------- --------------------- ------ ---- ------
  A                                 A (unidentified)     0                            0    
                                    AI                   0                            0    
                                    AII                  1                     5.6    4    9.3
  B                                 B (unidentified)     5                     27.6   19   44.2
                                    BIII                 1                     5.6    0    
                                    BIV                  1                     5.6    5    11.6
  Mixed types                       A+B                  1                     5.6    2    4.7
  (A+B)                             A+BIII               1                     5.6    0    
                                    A+BIV                0                            1    2.3
                                    AI+BIII              1                     5.6    0    
                                    AI+BIV               2                     11.1   0    
                                    AII+B                0                            7    16.3
                                    AII+BIII             4                     22.1   3    6.9
                                    AII+BIV              1                     5.6    2    4.7

![DNA-banding patterns (RFLP) of the 432-bp gdh amplicons cut by the Rsal restriction endonuclease](jhpn0028-0042_f03){#F3}

Demographic and clinical implications of different sub-assemblages {#sec1_3_4}
------------------------------------------------------------------

Of the 61 *G. intestinalis* cyst-positive subjects, 18 presented with gastrontestinal symptoms ([Table 1](#T1){ref-type="table"} and [5](#T5){ref-type="table"}), i.e. five (22.7%) of 22 Bangkok residents (Group 2) and 13 (33.3%) of 39 Ratchaburi inhabitants (Group 4). Three of the five Bangkok subjects had cyst assemblage A+B, and two had assemblage B only. Seven (53.9%) symptomatic subjects of the rural residents had mixed A+B cysts, five (38.5%) had B only, and one (7.6%) had A only. [Table 5](#T5){ref-type="table"} gives details on age, clinical diagnosis, and other parasites found in stools of the symptomatic subjects.

###### 

Age of subjects with gastrointestinal disturbances whose stool samples contained *Giardia intestinalis* only or with other parasite(s)

  Group                              No. of subjects   Age (years)   Clinical diagnosis/other parasite(s) found                         Assemblage(s)/sub-assemblage(s)
  ---------------------------------- ----------------- ------------- ------------------------------------------------------------------ ---------------------------------
  2                                  18                38            Abdominal pain, diarrhoea with soft stool*/Blastocystis hominis*   AII+BIII
  (Siriraj Hospital, Bangkok)        19                50            Abdominal pain with nausea, anaemia                                AII+BIV
                                     20                9             Diarrhoea, bronchitis                                              B
                                     21                54            Diarrhoea, chronic urticaria                                       B
                                     22                66            Diarrhoea with watery stool, hypertesion, dyslipidaemia            AI+BIV
  4                                  49                5             Diarrhoea*/Entameoba coli*                                         B
  (Community, Ratchaburi province)   50                3             Abdominal pain, diarrhoea with soft stool                          AII+BIII
                                     51                7             Diarrhoea                                                          A+B
                                     52                8             Abdominal pain, diarrhoea*/Endolimax nana*                         A+BIII
                                     53                2             Abdominal pain with nausea                                         BIV
                                     54                4             Abdominal pain, diarrhoea                                          BIII
                                     55                7             Abdominal pain, diarrhoea with soft stool*/Necator americanus*     AII+BIII
                                     56                6             Watery diarrhoea                                                   AI+BIII
                                     57                6             Diarrhoea                                                          B
                                     58                50            Watery diarrhoea*/B. hominis*                                      AII
                                     59                4             Abdominal pain, diarrhoea with soft stool                          AII+BIII
                                     60                5             Diarrhoea with watery stool                                        AI+BIV
                                     61                5             Diarrhoea*/E. histolytica, E. coli, E. nana*                       B

All the three (100%) subjects with mixed AI+BIII sub-assemblages (no. 56 of Group 4) or AI+BIV sub-assemblages (no. 22 of Group 2 and 60 of Group 4) had gastrointestinal symptoms. There were six (27%) symptomatic subjects among the 22 individuals with AII sub-assemblage. These subjects were no. 18 and 19 of Group 2 and no. 50, 55, 58, and 59 of Group 4. Of these two subjects, i.e. no. 18 of Group 2, aged 38 years, and no. 55 of Group 4, aged seven years, had mixed infection of *G. intestinalis* (AII+BIII) and *Blastocystis hominis*, and AII+BIII and hookworm *(Necator americanus)* respectively. No. 19 of Group 2, aged 50 years, and no. 50, 58, and 59 of Group 4, aged 3, 7 and 4 years, respectively, had AII+BIV, AII+BIII, AII alone, and AII+BIII.

Of the 10 (45.5%) subjects who had BIII sub-assemblage cysts, seven (70%) had gastrointestinal symptoms ([Table 5](#T5){ref-type="table"}), i.e. no. 18 of Group 2 and no. 50, 52, 54, 55, 56, and 59 of Group 4. One subject---no. 52, aged 8 years---had a mixed infection of *G. intestinalis* with *Endolimax nana*. Of the 12 subjects whose cysts were sub-assemblage BIV, four (33%) had gastrointestinal symptoms, and their stool samples revealed only *G. intestinalis* cysts ([Table 3](#T3){ref-type="table"}), i.e. no. 19 (AII+BIV) and 22 (AI+BIV) of Group 2 and no. 53 (BIV) and 60 (AI+BIV) of Group 4, aged 50, 66, 2 and 4 years respectively.

Five subjects with gastrointestinal symptoms had *G. intestinalis* cysts of B assemblage only, i.e. no. 20 and 21 of Group 2 and no. 49, 52, and 61 of Group 4. No. 49 had mixed infections of *G. intestinalis* with *Entamoeba coli,* and no. 61 had *G. intestinalis* with *E. histolytica, E. coli,* and *E. nana*.

The *G. intestinalis* sub-assemblages of all the symptomatic subjects were also verified by comparing the nucleotide sequences of their gene segment amplicons with the respective sequences of the GenBank database (data not shown).

Of the five symptomatic subjects of Group 2 (Bangkok inhabitants), four (80%) were adults, i.e. no. 18, 19, 21, and 22, aged 38, 50, 54, and 66 years respectively, and only one (20 %) was a child (no. 20, aged 9 years). Of these, only no. 18 had a mixed infection of *G. intestinalis* with *B. hominis*. It can, thus, be concluded that the most (80%) cases with symptomatic giardiasis in Group 2 were adult/elderly. Of the 13 symptomatic subjects of Group 4 (from communities of Ratchaburi province), 12 (92%) were children, and only one (8%, no. 58) was an adult aged 50 years. Of these 13 subjects, five had stool samples that revealed parasites other than *G. intestinalis*, i.e. no. 49 with *E. coli,* no. 52 with *E. nana*, no. 55 with hookworm, no. 58 with *B. hominis*, and no. 61 with *E. histolytica, E. coli,* and *E. nana*.

DISCUSSION {#sec1_4}
==========

Most human *Giardia*-associated infections occur through ingestion of parasite cysts in contaminated water or directly through faecal-oral transmission ([@B2], [@B23]). The infectious dose of the parasite can be as few as 10 cysts or less ([@B24]). Thus, water sanitation and personal hygiene determine the prevalence of giardiasis in a community ([@B25]). The results of this study showed that the prevalence of giardiasis in Thailand was much lower than previously reported which was as high as 37.7% in 2003 in Pathum-thani province at the outskirts of Bangkok ([@B17]) where inhabitants had a similar lifestyle to the Ratchaburi communities of this study who had a prevalence of 4.1%, which reflects improved sanitary conditions, healthcare, and health education in the country during recent years. Moreover, the prevalence of *Giardia*-associated infections among the Bangkok residents (0.36%) was about 10 times lower than that of the rural communities (4.1%). People living in Bangkok have easier access to clean water and proper waste disposal than many rural areas where some peasants still bath and wash their dishes and clothes in canals or rivers which are easily contaminated and where the parasite may flourish. Moreover, there are more pets, poultry, livestock, and other animals running around freely in rural communities serving as potential sources of human infections due to *Giardia* ([@B2]).

The molecular characterization of the *Giardia* spp. is useful for understanding the biology of the parasite, its host preferences, epidemiology, and pathogenicity ([@B2]). However, information on *G. intestinalis* isolates of humans and animals and their genotypes in Thailand is scarce. In this study, PCR-based genotyping of *G. intestinalis* cysts was performed. The genomic DNA extracted from the cysts of the subjects were used as templates in a one-step PCR for the amplification of the 148- and 81-bp *tpi* gene segments for determining assemblage A and B respectively ([@B19]). This single-step PCR of the *tpi* gene segments for assemblage classification was simple and rapid. It was also highly sensitive (sensitivity 100%) compared to the two-step PCR performed on DNA extracted from the whole faeces, using a different set of primers, with a sensitivity of 94% for sporadic cases and 88% for samples of a nursery outbreak ([@B26]). The assemblage identification of the cysts from 61 *G. intestinalis*-infected subjects revealed that 8% (5 of 61) of the cyst preparations were assemblage A only, 51% (31 of 61) were assemblage B only, and 41% (25 of 61) were a mixture of assemblage A and B. Our findings conformed to the notion that, although the *Giardia* spp. are heterogeneous and can be classified into A-G assemblages which infect a wide range of hosts, only the assemblage A and B are contagious for humans ([@B6], [@B23]). Altogether, 30 individuals harboured cysts of assemblage A, or A+B mixture and 56 individuals with B or A+B cysts. The prevalence of assemblage B infection was almost twice as high as that of assemblage A infection. These data are similar to studies carried out in Bangladesh ([@B14]), the Philippines ([@B27]), India ([@B15]), England ([@B28]), the Netherlands ([@B29]), and Brazil ([@B30]) but are different from data reported from Korea ([@B31]) and Mexico ([@B32]) where assemblage A was predominant.

A further classification of the cysts into A and B sub-assemblages based on RFLP of the 384-bp β-*giardin* and 432-bp *gdh* gene segments respectively showed that cysts of only three subjects (12%) belonged to sub-assemblage AI, most (88%) belonged to sub-assemblage AII, and cysts of 10 (45.5%) and 12 (54.5%) subjects belonged to the BIII and BIV sub-assemblages respectively. Earlier reports indicated that the AI sub-assemblage and the B assemblage, regardless of the B sub-assemblages, have a broad host range, including pets, wildlife, and livestock while the AII sub-assemblage is more limited to human subjects ([@B2], [@B33]). Thus, it is possible that the AI and B infections found in this study were zoonotic while the AII infections were anthroponotic.

Although there was no clear-cut correlation of assemblages and sub-assemblages with symptomatic giardiasis in this study ([Table 5](#T5){ref-type="table"}), all the three subjects with AI sub-assemblage, either AI+BIII (no. 56, aged 6 years) or AI+BIV (no. 22, aged 66 years and no. 60, aged 5 years) had gastrointestinal symptoms. The stool sample of subject no. 18 also had *B. hominis* which is regarded as a potential pathogen and may occasionally cause abdominal pain, nausea, bloating and/or diarrhoea; therefore, the gastrointestinal symptoms experienced by this subject might have been due to the organism that co-infected. Nevertheless, the two (66%) remaining subjects who had only *G. intestinalis*-associated infection with sub-assemblage AI+BIII and AI+BIV had symptomatic giardiasis. Seventy percent of the subjects with BIII sub-assemblage, either BIII alone, AI+BIII, or AII+BIII, had gastrointestinal symptoms. Four of these seven subjects had *Giardia* cysts only, and no other pathogens were found in their stool samples while three subjects had mixed infections of *G. intestinalis* with *B. hominis* (no. 18), *E. nana* (no. 52), and hookworm (no. 55). *B. hominis* and hookworm can cause diarrhoea and other gastrointestinal disturbances while *E. nana* is non-pathogenic for humans. Thus, five of the seven subjects with sub-assemblage BIII may be regarded as symptomatic giardiasis. The *in vivo*-expressed antigens/virulence factors, the host-parasite interplay, and the host factors determining the susceptibility to *G. intestinalis* at a molecular level need further elucidation.

Only one (20%) of the five symptomatic subjects of the Bangkok group was a child (no. 20, aged 9 years) while the other four subjects were aged 66, 38, 50, and 54 years. The reverse picture was seen for the symptomatic subjects of the Ratchaburi group, i.e. only one (8%) of the 13 symptomatic subjects was elderly (no. 58, aged 50 years) while the remaining 12 subjects (92%) were children aged 2--7 years. Our findings conformed to data previously reported from other countries that symptomatic giardiasis is mainly confined to the young and the elderly ([@B34], [@B35]). Reasons usually given to explain the susceptibility of these age-groups are the immaturity of the immunological apparatus in the former and the (replicative) immune senescence/immune incompetence of the latter ([@B36], [@B37]). Nevertheless, other parasite factors and host factors and their interplay have also been suggested as contributing to the pathophysiology observed in clinical giardiasis ([@B37]). During an infection, a clone of *Giardia* spp. may diversify into a complex mixture of different antigenic types ([@B38]) and depending upon both host immunological factors, such as specific secretory IgA, and non-immunological factors, such as the intestinal protease, the *Giardia* trophozoite variant(s) that can resist the hostile environment in the intestines, would proliferate and cause morbidity ([@B38]). Moreover, *Giardia* lectin promotes adherence of the parasite to the intestinal brush border, and the parasite uses the ventral sucker disc to colonize the epithelium ([@B38]), which consequently may cause acute/chronic diarrhoea, steatorrhoea, and malabsorption and, in a prolonged infection, lead to growth retardation depending on the burden of parasite and its virulence. There is a possibility that *Giardia* produce a toxin or at least metabolic products that may contribute to their pathogenicity ([@B39]). Obviously, much more is to be learnt about this inscrutable parasitic infection. This study provides a baseline message on genotypes of the isolates of *G. intestinalis* from humans in Thailand and also demonstrates a correlation of symptomatic giardiasis with age of the host.
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